Georges Gemayel, Ph.D., President and Chief Executive Officer
Burkhard Blank, M.D., Executive Vice President and Chief Medical Officer
Jonathan I. Lieber, Senior Vice President, Chief Financial Officer and Treasurer
Phil Gotwals, Ph.D., Vice President, Program Management
John M. Sorvillo, Ph.D., Vice President, Business Development

Georges Gemayel, Ph.D.

President and Chief Executive Officer

Dr. Gemayel was appointed President and Chief Executive Officer and to the Company’s Board of Directors, effective June 2, 2008. Dr. Gemayel joins Altus Pharmaceuticals from Genzyme Corporation where he was Executive Vice President and a corporate officer. Dr. Gemayel joined Genzyme in 2003. He was responsible for the company’s therapeutics, transplant, renal and biosurgery businesses. Before he joined Genzyme, Dr. Gemayel worked for the health care company Hoffman-LaRoche for 16 years. There he served as Vice President of the U.S. Specialty Care Business with responsibilities for oncology, transplantation, hepatitis, HIV and dermatology. He also was the general manager of Hoffman-LaRoche, Portugal. Dr. Gemayel completed his doctorate in pharmacy at St. Joseph University in Beirut and earned a Ph.D. in pharmacology at Paris-Sud University.

Burkhard Blank, M.D.

Executive Vice President and Chief Medical Officer

Dr. Blank has served as our Executive Vice President and Chief Medical Officer since January of 2008. Dr. Blank joined Altus in June 2006 as the Senior Vice President of Medicine, Regulatory Affairs, and Project Management. Prior to joining Altus, Dr. Blank served as the Senior Vice President for Medicine and Drug Regulatory Affairs at Boehringer Ingelheim Pharmaceuticals USA, where he successfully managed the many components of an extensive clinical research program. Dr. Blank was responsible for a staff of 600 and an annual recruitment of 8,000-10,000 patients in the North and South America region. Prior to his position in the USA, he held a number of positions with increasing levels of responsibility at Boehringer’s headquarters in Ingelheim, Germany, the most recent as Head of Division International Project Management and Drug Regulatory Affairs (DRA). In this capacity, he founded the International Project Management Department, which had worldwide responsibility for the planning and monitoring of all Phase I-IV development projects and for all international regulatory submissions. Dr. Blank was also a member of Boehringer’s International Development Committee, which was responsible for steering their global drug development portfolio. He holds a medical degree in internal medicine from Universitaet Marburg, Germany.

Jonathan I. Lieber

Senior Vice President, Chief Financial Officer and Treasurer

Jonathan I. Lieber currently serves as our Senior Vice President, Chief Financial Officer and Treasurer. Mr. Lieber joined us in July 2002 as our Vice President, Finance. From 1998 to June 2002, Mr. Lieber was a member of SG Cowen’s Health Care Investment Banking Group, most recently as a vice president focused on the biotechnology and specialty pharmaceuticals sectors. Prior to joining SG Cowen, Mr. Lieber was a member of the Health Care and High Yield Groups at Salomon Brothers Inc. Mr. Lieber received an M.B.A. in finance from the Stern School of Business of New York University and a B.Sc. in business administration from Boston University.

Phil Gotwals, Ph.D.

Vice President, Program Management

Dr. Gotwals has served as our Vice President of Program Management since January 2008. Dr. Gotwals joined Altus in September 2006 as the Vice President of Project Management. Dr. Gotwals has 14 years of scientific and project management experience in the biotechnology industry. Before joining Altus, Dr. Gotwals was Senior Director of Early Development in the Department of Program and Alliance Management at Biogen Idec. Dr. Gotwals holds a Ph.D. in Genetics from the University of California, Berkeley and a B.A. in Biology from Amherst College.

John M. Sorvillo, Ph.D.

Vice President, Business Development

John M. Sorvillo, Ph.D. has served as our Vice President of Business Development since August 2006. Before joining us, Dr. Sorvillo served as Chief Executive Officer of Bionaut Pharmaceuticals. From 1995 to 2005, Dr. Sorvillo acted as Vice President of Business Development at ArQule, where he was responsible for establishing corporate collaborations with pharmaceutical companies. Prior to that, Dr. Sorvillo held a variety of positions at OSI Pharmaceuticals (formerly Oncogene Science) leading up to his last position as Vice President and General Manager, Research Products Division. Dr. Sorvillo was a postdoctoral fellow at Memorial Sloan Kettering Cancer Center and received his Ph.D. in Immunology from the New York University Medical Center, Sackler Institute of Biomedical Sciences. He holds a B.A. in Biology from the City University of New York, Hunter College.